The assessment of back muscle capacity using intermittent static contractions. Part II: Validity and reliability of biomechanical correlates of muscle fatigue

IntroductionIn a previous paper, standard surface electromyographic (EMG) indices of muscle fatigue, which are based on the lowering of the median or mean frequencies of the EMG power spectrum in time, were applied during an intermittent absolute endurance test and were evaluated relative to criterion validity and test–retest reliability. The aims of this study were to assess mechanical and alternative EMG correlates of muscle fatigue.MethodsHealthy subjects (44 males and 29 females; age: 20–55 yrs) performed three maximal voluntary contractions (MVC) and an endurance test while standing in a static dynamometer. Surface EMG signals were collected from four pairs of back muscles (multifidus at the L5 level, iliocostalis lumborum at L3, and longissimus at L1 and T10). The test, assessing absolute endurance (90 N m torque), consisted of performing an intermittent extension task to exhaustion. Strength was defined as the peak MVC whereas our endurance criterion was defined as the time to reach exhaustion (Tend) during the endurance test. Mechanical indices quantifying physiological tremor and steadiness were computed from the dynamometer signals (L5/S1 extension moments) along with EMG indices presumably sensitive to variable load sharing between back muscle synergists during the endurance test.ResultsMechanical indices were significantly correlated to Tend (r range: −0.47 to –0.53) but showed deceiving reliability results. Conversely, the EMG indices were correlated to Tend (r range: −0.43 to –0.63) with some of them particularly correlated to Strength (r = − 0.72 to –0.81). In addition, their reliability results were acceptable (intra-class correlation coefficient >0.75; standard error of measurement <10% of the mean) in many cases. Finally, several analyses substantiated their physiological relevance. These findings imply that these new EMG indices could be used to predict absolute endurance as well as strength with the use of a single intermittent and time-limited (5–10 min) absolute endurance test, a practical way to assess the back capacity of chronic low back pain subjects.     

Vascular smooth muscle cell proliferation as a therapeutic target. Part 2: Natural products inhibiting proliferation

Many natural products have been so far tested regarding their potency to inhibit vascular smooth muscle cell proliferation, a process involved in atherosclerosis, pulmonary hypertension and restenosis. Compounds studied in vitro and in vivo as VSMC proliferation inhibitors include, for example indirubin-3′-monoxime, resveratrol, hyperoside, plumericin, pelargonidin, zerumbone and apamin. Moreover, taxol and rapamycin, the most prominent compounds applied in drug-eluting stents to counteract restenosis, are natural products. Numerous studies show that natural products have proven to yield effective inhibitors of vascular smooth muscle cell proliferation and ongoing research effort might result in the discovery of further clinically relevant compounds.     

Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways

Cardiovascular diseases are a major cause of human death worldwide. Excessive proliferation of vascular smooth muscle cells contributes to the etiology of such diseases, including atherosclerosis, restenosis, and pulmonary hypertension. The control of vascular cell proliferation is complex and encompasses interactions of many regulatory molecules and signaling pathways. Herein, we recapitulated the importance of signaling cascades relevant for the regulation of vascular cell proliferation. Detailed understanding of the mechanism underlying this process is essential for the identification of new lead compounds (e.g., natural products) for vascular therapies.     

On a nonlinear theory for muscle shells: Part I--Theoretical development

This paper presents a theory for studies of the large-strain behavior of biological shells composed of layers of incompressible, orthotropic tissue, possibly muscle, of arbitrary orientation. The intrinsic equations of the laminated-shell theory, expressed in lines-of-curvature coordinates, account for large membrane [O(1)] and moderately large bending and transverse shear strains [O(0.3)], nonlinear material properties, and transverse normal stress and strain. An expansion is derived for a general two-dimensional strain-energy density function, which includes residual stress and muscle activation through a shifting zero-stress configuration. Strain-displacement relations are given for the special case of axisymmetric deformation of shells of revolution with torsion.     

Glycopeptide dendrimers. Part I.

Glycopeptide dendrimers are branched structures containing both carbohydrates and peptides. Various classes of these compounds differing in composition and structure are mentioned, together with their practical use spanning from catalysis, transport vehicles to synthetic vaccines. The main stress is given to glycopeptide dendrimers, namely multiple antigen glycopeptides (MAGs). In MAGs, the core, branches or both are composed of amino acids or peptides. Other classes of glycodendrimers (PAMAM, polypropylene imine, cyclodextrin, calixarene, etc.) are mentioned too, but to a smaller extent. Their syntheses, physicochemical properties and biological activities are given with many examples. Glycopeptide dendrimers can be used as inhibitors of cell surface protein-carbohydrate interactions, intervention with bacterial adhesion, for studying of recognition processes, diagnostics, imaging and contrast agents, mimetics, for complexation of different cationts, as site-specific molecular delivery systems, for therapeutic purposes, as immunodiagnostics and in drug design. Biomedical applications of glycopeptide dendrimers as drug and gene delivery systems are also given.     

Glycopeptide dendrimers. Part II.

Glycopeptide dendrimers are regularly branched structures containing both carbohydrates and peptides. Various types of these compounds differing in composition and structure are mentioned, together with their practical use spanning from catalysis, transport vehicles to synthetic vaccines. This Part II (for Part I see JeZek J, et al., J. Pept. Sci. 2008; 14: 2-43) covers linear oligomers with variable valency (brush dendrimers, comb dendrimers), sequential oligopeptide carriers SOCn-I and SOCn-II, chitosan-based dendrimers, and brush dendrimers. Other types of glycopeptide dendrimers are self-immolative dendrimers (cascade release dendrimers, domino dendrimers), dendrimers containing omega-amino acids (Gly, beta-Ala, gamma-Abu and epsilon-aminohexanoic acid), etc. Microwave-assisted synthesis of dendrimers and libraries of glycopeptides and glycopeptide dendrimers are also included. Characterization of dendrimers by electromigration methods, mass spectrometry, and time-resolved and nonlinear optical spectroscopy, etc. plays an important role in purity assessment and structure characterization. Physicochemical properties of dendrimers including chirality are given. Stability of dendrimers, their biocompatibility and toxicity are reviewed. Finally, biomedical applications of dendrimers including imaging agents (contrast agents), site-specific drug delivery systems, artificial viruses, synthetic antibacterial, antiviral, and anticancer vaccines, inhibitors of cell surface protein-carbohydrate interactions, intervention with bacterial adhesion, etc. are given. Glycopeptide dendrimers were used also for studying recognition processes, as diagnostics and mimetics, for complexation of different cations, for therapeutic purposes, as immunodiagnostics, and in drug design.     

Bone marrow transplantation. Part II--autologous.

Autologous bone marrow transplantation provides an effective form of "rescue" following high-dose therapy used for treating certain malignant diseases. The high doses of radiotherapy or chemotherapy, or both, should allow for greater tumor cell kill if dose-response to therapy exists for that tumor. The use of autologous bone marrow obviates the need for an HLA-identical donor, and the need for pretransplant immunosuppression; no graft-versus-host disease would ensue. We review in part II the history and background, methods of obtaining autologous stem cells, and details of the results achievable with this type of therapy. We discuss potential difficulties with autologous transplantation, as well as possible future areas of research.